Skip to search formSkip to main contentSkip to account menu

BG 00012

Known as: 00012, BG, BG-00012, BG00012 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dimethyl fumarate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Dimethylfumarate Protects from Oxidative Stress by Increasing Glutathione (P02.120)
Objective: To evaluate the mechanism of action of dimethylfumarate (DMF), a novel oral therapeutic for the treatment of multiple… 
2010
2010
Emerging Therapies in Multiple Sclerosis—New Decisions in the Formulation of Treatment Strategies
Disease-modifying therapies (DMTs) for treating multiple sclerosis (MS) are entering a period of rapid and profound change that… 
Review
2010
Review
2010
Current and future role of interferon beta in the therapy of multiple sclerosis.
Interferon beta was the first specific disease-modifying therapy licensed for multiple sclerosis (MS) and in its many forms… 
2008
2008
The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions
2008
2008
The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study
2008
2008
Safety profile of BG00012, all oral formulation of dimethyl fumarate for patients with relapsing MS
2008
2008
BG00012: AN EMERGING ORAL THERAPY FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS
Traditional disease-modifying therapies (DMTs) for MS have pleiotropic effects on the disease pathophysiology including… 
2005
2005
A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy, BG00012, in patients with relapsing-remitting multiple sclerosis
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)